IODOMETRIC DETERMINATION OF CEFUROXIME BY THE POTASSIUM HYDROGENPEROXOMONOSULPHATE REACTION

Yu.Yu.Serdiukova, M.M.Ivashura, T.O.Oleksienko
National University of Pharmacy

Key words: cefuroxime; iodometric determination; potassium hydrogenperoxomonosulphate

Simple methods for oxidimetric determination of antibiotic Cefuroxime in the substance and in the powder for solution for injection, which are based on the S-oxidation reaction by potassium hydrogenperoxomonosulphate in a weak acidic medium to S-oxide with the subsequent determination of the residual oxidising agent by the iodometric method, have been developed. A triple potassium salt of Caro’s acid, 2KHSO₅•KHSO₄•K₂SO₄, was used as an oxidising agent. Quantitative oxidation of the Sulphur atom completes during the period that is less than 1 min. The mean recovery of the active ingredient in the substance of cefuroxime was 98.67%, RSD = 0.57% (δ = 0.33%). The mean recovery of the medicine “Cefuroxime”, 750 mg, is 782.8 mg, RSD = 0.97% (δ = 0.91%), which should be 680-900 mg calculated with reference to dried substance. The LOQ is С = 0.05 mg mL⁻¹. The advantages of the method proposed are the ability of analytical determination of cefuroxime by the biologically active part of the molecule, namely alicyclic Sulphur, good precision and accuracy of the results. The validation data obtained meet the requirements of the State Pharmacopoeia of Ukraine, they indicate the possibility of its introduction in the practice of analytical laboratories analysis, application during the stepwise control process of drug manufacturing or the quality control during equipment washing.

Cefuroxime (Cefuroxim), (6R,7R)-3-[(aminocarbonyl)oxy]methyl]-7-[(2E)-2-furan-2-yl-2-[(methyloxy)imino]acetyl]amino)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, is a derivative of 7-ADCC and belongs to semisynthetic cephalosporin β-lactam antibiotics of the II generation. The EPh and BP recommend to determine cefuroxime using the method of HPLC [3, 6].

The classical iodometric titration method is long lasting and unreliable [1]. The extensive literature survey reveals several procedures of cefuroxime determination in medicines using liquid chromatography [12], capillary electrophoresis [8], polarography [2], and spectrofluorimetry [9]. A lot of spectrophotometric [4, 5, 11] and titrimetric [10, 7] methods for quantitative determination of cefuroxime have been developed.

The aim of the study was to develop a new method for quantitative determination of cefuroxime in the substance and the powder for solution for injection by oxidimetry using potassium hydrogenperoxomonosulphate as an analytical reagent (KHSO₅).

Materials and Methods
A triple potassium salt of Caro’s acid, 2KHSO₅•KHSO₄•K₂SO₄ (the trade name – “Oxon” manufactured by DuPont), was used as an oxidising agent. The active substance is potassium hydrogenperoxomonosulphate, KHSO₅. The choice of the reagent was determined by its rather high oxidative activity, $E_0 = 1.84$ V, availability, and satisfactory solubility in water.

1. Potassium hydrogenperoxomonosulphate solution, 0.02 Mol L⁻¹. Dissolve 0.615 g of 2KHSO₅•KHSO₄•K₂SO₄ in 50 mL of distilled water in a 100 mL volumetric flask. Dilute to the volume with water at 20°C.

The content of KHSO₅ in the solution prepared was determined by iodometric titration [3].

2. Sodium thiosulphate solution, 0.02 Mol L⁻¹. Prepare 0.1 Mol/L⁻¹ of the sodium thiosulphate solution from the standard titre fixanal. Pipette 20 mL of the solution obtained and transfer into a 100 mL volumetric flask. Dilute to the volume with water at 20°C.

3. Potassium iodide solution, 5%. Dissolve 5.0 g of the sample weight of potassium iodide in 50 mL of distilled water in a 100 mL volumetric flask. Dilute to the volume with water at 20°C.

4. Sulphuric acid solution, 0.1 Mol L⁻¹. Prepared from the standard titre fixanal in a 500 mL volumetric flask.

The method for studying the S-oxidation reaction kinetics. Pipette 10.0 mL of 0.02 Mol L⁻¹ potassium hydrogenperoxomonosulphate solution, transfer in a 100 mL volumetric flask, add 10.0 mL of 0.01 Mol/L⁻¹ cefuroxime solution and switch on a stop watch. Dilute to the volume with distilled water and mix thoroughly. At specific time intervals pipette 10 mL of the mixture obtained, transfer in a flask for titration, acidify with 1 mL of 0.1 Mol/L⁻¹ sulphuric acid solution and add 1 mL of 5%
potassium iodine solution. Titrate the iodine liberated with 0.02 Mol/L\(^{-1}\) of the titrated solution of sodium thiosulphate in the presence of starch.

The medicine Cefuroxime, powder for solution for injection, 0.75 g, manufactured by “Lekchim-Kharkov”, the batch 10712230412 was used.

The titrant volume was measured using a 10 mL micropipette with the accuracy of \(\pm 0.01\) mL.

**Assay for cefuroxime in the powder for preparing the solution for injection.** Dissolve 0.43 g (accurate weight) of the powder of the medicine with the known moisture content (\(w, \%\)) in 70 mL of distilled water and dilute the volume to 100.00 mL. Transfer 10.00 mL into a 100 mL volumetric flask, add 10.00 mL of 0.02 Mol/L\(^{-1}\) KH\(\text{SO}_4\) solution, dilute the volume with distilled water, mix thoroughly and leave for 1 min. Then transfer 10.00 mL of the solution obtained into a flask for titration, add 1 mL of 0.1 Mol L\(^{-1}\) sulphuric acid solution and 1 mL of 5% potassium iodine solution. Titrate the iodine liberated with 0.02 Mol/L\(^{-1}\) of sodium thiosulphate solution (\(V, \text{mL}\)).

Simultaneously the control experiment was carried out under similar condition (without cefuroxime with the same amount of 0.02 Mol/L\(^{-1}\) of KH\(\text{SO}_4\) solution (\(V_m, \text{mL}\)).

The content of cefuroxime in the powder for solution for injection \(X (\text{g})\) was calculated by the formula:

\[
X = \frac{\left(V - V_m\right) \cdot K \cdot T \cdot m \cdot 100 - 100 \cdot 100}{2 \cdot m_s \cdot \left(100 - w\right) \cdot 10 \cdot 10},
\]

where: \(V_0\) – is the volume of the standard 0.02 Mol/L\(^{-1}\) sodium thiosulphate solution used for titration in the control experiment, mL; \(V\) – is the volume of the standard 0.02 Mol/L\(^{-1}\) sodium thiosulphate solution used for titration in the experiment with cefuroxime, mL; \(K\) – is the correlation coefficient of the concentration for the standard 0.0200 Mol/L\(^{-1}\) sodium thiosulphate solution; \(T\) – is the cefuroxime weight corresponding to 1.00 mL of the standard 0.0200 Mol/L\(^{-1}\) sodium thiosulphate solution, g/mL\(^{-1}\); 100 and 10 – are the volumes of the volumetric flask and aliquots of the solution taken for analysis, mL; \(m_s\) – is the sample weight, g; \(m\) – is the average weight of the vial, g; \(w\) – is the moisture content in the medicine, %.

1.00 mL of the standard 0.0200 Mol/L\(^{-1}\) sodium thiosulphate solution correspond to 0.004244 g of cefuroxime (C\(_{16}\)H\(_{16}\)N\(_4\)O\(_8\)S), the medicine should contain 0.68-0.90 g calculated with reference to dried substance.

**Results and Discussion**

The peroxyacidic method proposed is based on the reaction of Cefuroxime oxidation by the excess of KH\(\text{SO}_4\) with quantitative formation of the corresponding S-oxide in the acidic medium. The KH\(\text{SO}_4\) excess was determined by the method of iodometric titration.

It has been determined that the redox interaction between cefuroxime and potassium hydrogenperoxomonosulphate occurs quantitatively and stoichiometrically: 1 Mol of KH\(\text{SO}_4\) per 1 Mol of the medicine.

Quantitative oxidation of the Sulphur atom completed during the period that did not exceed 1 min by the method of iodometric titration.

The scheme of the S-oxidation reaction of cefuroxime using potassium hydrogenperoxomonosulphate is given in Fig.

**Table**

The results of quantitative determination of cefuroxime in the substance and in the powder for solution for injection (\(P = 0.95\))

| Taken | Found | Metrological characteristics |
|-------|-------|-----------------------------|
|       |       | Cefuroxime substance, %      |
| 99.00%| 99.10 | \(\overline{x} = 98.67\)  |
|       | 99.10 | \(S = 0.57\)               |
|       | 99.10 | \(S_\Delta = 0.252\)        |
|       | 98.07 | \(\text{RSD} = 0.073\%\)    |
|       | 98.07 | \(\epsilon = 0.71\%\)      |
|       |       | \(\delta = -0.33\%\)       |
| 0.7900| 0.7705| \(\overline{x} = 0.7828\)  |
|       | 0.7705| \(S = 0.0759\)             |
|       | 0.7869| \(S_\Delta = 0.0027\)       |
|       | 0.7869| \(\text{RSD} = 0.0064\%\)  |
|       | 0.7869| \(\epsilon = 0.82\%\)      |
|       | 0.7869| \(\delta = 0.91\%\)       |

*The content of the active substance was determined by the HPLC method given in the certificate.*

The results of quantitative determination of cefuroxime in the substance and in the medicine are given in Table. They show that the methods developed allow to determine the content of cefuroxime in the substance and the powder for solution for injection, 0.75 g, RSD = 0.57\%\(\pm0.97\%\), \(\delta = 0.3\%\pm0.91\%\).

The Limit of Quantification (LOQ) is 0.05 mg mL\(^{-1}\).

The advantages of the method proposed are the ability of analytical determination of cefuroxime by the biologically active part of the molecule, namely alicyclic Sulphur, good precision and accuracy of the results. It does not require the use of expensive reference standards, toxic solvents and special equipment as in the HPLC method. It is simple and rapid in application.

**CONCLUSIONS**

It has been proposed to use potassium hydrogenperoxomonosulphate as an analytical reagent for cefuroxime.

The methods for oxidimetric determination of the active ingredient in the substance and in Cefuroxime, powder for solution for injection, 0.75 g, which are based on the S-oxidation reaction by potassium hydrogen-
peroxomonosulphate in the acidic medium to the corresponding S-oxide with the subsequent determination of the residual oxidising agent by the iodometric method, have been proposed and developed (RSD = 0.57÷0.97%, δ = 0.3÷0.91%). The Limit of Quantification (LOQ) is 0.05 mg mL⁻¹.

REFERENCES

1. Арзамасцев А.П. Фармацевтическая химия: Учеб. пособ. / Под ред. А.П.Арзамасцев. – М.: ГЭОТАР-МЕД, 2004. – 640 с.
2. Bernacca G., Nucci L., Pergola F. // Electroanal. – 1994. – Vol. 6, №4. – P. 327-332.
3. British Pharmacopoeia. – London: The Stationery Office, 2009. – 10952 p.
4. Chaudari S.V., Karnik A., Adhikary A. et al. // Ind. J. Pharm. Sci. – 2006. – Vol. 6, №1. – P. 59-63.
5. El-Gindy A1., El-Walily A.F., Bedair M.F. // J. Pharm. Biomed. Anal. – 2000. – Vol. 23, №2-3. – P. 341-352.
6. European Pharmacopoeia. Vol. 1-2 / European Directorate for the Quality of Medicines & Health Care. – Strassbourg: – Council of Europe, 2010. – 3536 p.
7. Helaleh M.I.H., Abu-Named E.S.M., Jamhour R.M.A.Q. // Acta Pol. Pharm. Drug Res. – 1998. – Vol. 55, №2. – P. 93-97.
8. Mrestani Y., Neubert R.H., Härtl A. et al. // Anal. Chim. Acta. – 1997. – Vol. 349. – P. 207-213.
9. Murillo J.A., Lemus J.M., Garcia L.F. // J. Pharm. Biomed. Analysis. – 1994. – Vol. 12, №7. – P. 875-881.
10. Pospisilova B., Kubes J. // Pharmazie. – 1998. – Vol. 43, №4. – P. 246-248.
11. Rezowanur R.M., Asaduzzaman M., Ashraful S.M. // Am. J. Pharm. Tech. Res. – 2012. – Vol. 2, №4. – P. 351-358.
12. Shaha N.J., Shaha S.K., Patel V.F. et al. // Ind. J. Pharm. Sci. – 2007. – Vol. 69, №1. – P. 140-142.